tiprankstipranks
Trending News
More News >
Invivyd (IVVD)
NASDAQ:IVVD
US Market

Invivyd (IVVD) AI Stock Analysis

Compare
532 Followers

Top Page

IV

Invivyd

(NASDAQ:IVVD)

Rating:44Neutral
Price Target:
Invivyd's overall stock score reflects significant financial and technical weaknesses, marked by ongoing losses and bearish trends. While recent corporate developments offer a glimpse of potential strategic improvement, these are overshadowed by the current financial instability and weak market sentiment.
Positive Factors
Clinical Trials
Long-term data from the Phase 3 trial reported a 76% risk reduction in symptomatic COVID-19 over 12 months in immunocompetent individuals, suggesting broad protective durability.
Earnings
Net revenue from PEMGARDA rose 48% sequentially in 4Q24, reflecting growing prescriber adoption and renewed confidence.
Product Development
Early Phase 1 data for VYD2311 highlighted an average 17-fold improved potency vs. PEMGARDA, with potential advantages for long-acting, patient-friendly dosing.
Negative Factors
Launch Concerns
The initial launch trajectory of PEMGARDA fell short of expectations, leading to a lowered price target.
Market Risks
There is a 75% risk adjustment on the COVID-19 prophylaxis franchise starting in 2026, capturing the risk tied to emerging COVID-19 variants.
Regulatory Challenges
The FDA has rejected Invivyd’s submission to expand PEMGARDA's Emergency Use Authorization to include COVID-19 treatment.

Invivyd (IVVD) vs. SPDR S&P 500 ETF (SPY)

Invivyd Business Overview & Revenue Model

Company DescriptionInvivyd, Inc. (IVVD) is a biotechnology company that focuses on the discovery, development, and commercialization of innovative therapies for infectious diseases. The company's core products include monoclonal antibodies designed to treat and prevent viral infections, with a particular emphasis on addressing unmet medical needs in the field of infectious disease prevention and treatment.
How the Company Makes MoneyInvivyd generates revenue primarily through the development and commercialization of its therapeutic products. The company invests in research and development to create proprietary monoclonal antibodies that can be licensed or sold to healthcare providers, pharmaceutical companies, or directly to the market. Revenue streams may include product sales, licensing agreements, and potential partnerships or collaborations with other pharmaceutical companies. These partnerships can involve co-development or co-marketing arrangements, which can significantly contribute to the company's earnings by leveraging shared resources and expertise.

Invivyd Earnings Call Summary

Earnings Call Date:May 15, 2025
(Q1-2025)
|
% Change Since: -11.90%|
Next Earnings Date:Aug 19, 2025
Earnings Call Sentiment Neutral
The earnings call highlighted the successful internalization of the commercial team, pipeline expansion, and strong financial management. However, these positives were offset by a decline in Q1 revenue, regulatory hurdles with EUA expansion, and challenges in healthcare provider adoption. The company expressed confidence in its strategic direction and financial discipline but faces significant challenges in execution and regulatory approval.
Q1-2025 Updates
Positive Updates
Internalization of Commercial Organization
The company successfully transitioned to an internal commercial team, which is expected to drive broader adoption of PEMGARDA, with promising early indicators for near-term breakeven and continued revenue growth.
Pipeline Expansion and Discovery Programs
The company expanded its pipeline to include discovery programs targeting new viral diseases such as RSV and measles, aiming to create best-in-class medicines beyond COVID-19.
Strong Financial Position and Cost Management
The company reported $11.3 million in net product revenue for Q1 2025 and a reduction in operating expenses by 15% quarter-over-quarter, with a strong cash position of $48 million and potential access to $30 million in non-dilutive funding.
Inclusion in Clinical Guidelines
PEMGARDA has been included in the NCCN Guidelines for B-cell lymphomas, indicating recognition from medical guidelines for its usage.
Negative Updates
Q1 Revenue Decline
PEMGARDA net product revenue dipped in Q1 2025 compared to Q4 2024, attributed to the transition to an internal sales force and the temporary lack of sales activity.
Regulatory Challenges with EUA
The FDA declined the expansion of EUA for PEMGARDA to include treatment of active mild-to-moderate COVID in immunocompromised persons, citing uncertainties in clinical benefits and optimal dosing.
Skepticism and Challenges in Healthcare Provider Adoption
Healthcare providers exhibited skepticism regarding the effectiveness of PEMGARDA, particularly after the FDA inserted inaccurate data into its fact sheet, creating challenges in re-educating the medical community.
Company Guidance
During Invivyd’s First Quarter 2025 Earnings Conference Call, the company provided guidance that emphasized the transition to an internal commercial organization, aiming for near-term breakeven with ongoing revenue growth and operating expense management. The management highlighted a strategic focus on broader adoption of PEMGARDA, with promising leading indicators for commercial success. Invivyd secured additional non-dilutive capital contingent on meeting certain conditions and milestones and is expanding its pipeline beyond COVID-19, including discovery programs in new viral targets and diseases such as RSV and measles. The company's strategy includes disciplined financial management, targeting profitability by mid-2025, and leveraging its scientific platform to create shareholder value efficiently. The guidance reflects a commitment to developing high-value medicines rapidly, despite the challenging biotech financing environment.

Invivyd Financial Statement Overview

Summary
Invivyd faces substantial financial challenges with significant losses and negative cash flows, despite recent revenue generation. While the balance sheet shows low leverage and strong cash reserves, consistent operational losses and cash flow inefficiencies pose considerable risks. Strategic improvements are critical for future stability.
Income Statement
35
Negative
Invivyd's financial performance shows a challenging trajectory. The company recorded its first revenue of $25.38 million in 2024 after having no revenue in previous years, indicating a significant growth. However, the company still faces substantial net losses, with a negative net profit margin due to high operational costs. The EBIT and EBITDA margins are also negative, reflecting operational inefficiencies.
Balance Sheet
45
Neutral
Invivyd maintains a relatively strong equity position with a moderate debt load, as evidenced by a low debt-to-equity ratio. However, there has been a significant decrease in stockholders' equity over the years, and the equity ratio has declined, indicating potential risks if losses continue. The company's high cash reserves provide some financial stability.
Cash Flow
40
Negative
The company's cash flow situation is strained, with consistently negative free cash flow due to high operational cash outflows. The free cash flow to net income ratio remains unfavorable, indicating that the company is not generating cash from its operations. However, there is a positive trend in financing activities which have supported cash reserves.
BreakdownTTMDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue36.69M25.38M0.000.000.000.00
Gross Profit34.24M23.77M-2.03M-462.00K-1.00K0.00
EBITDA-145.63M-173.76M-196.62M-248.03M-226.79M-65.33M
Net Income-142.72M-169.93M-198.64M-234.60M-234.29M-65.32M
Balance Sheet
Total Assets103.74M129.51M229.18M383.17M620.09M117.38M
Cash, Cash Equivalents and Short-Term Investments48.08M69.35M200.64M371.99M591.42M114.99M
Total Debt894.00K1.30M2.17M3.72M0.000.00
Total Liabilities49.59M61.98M51.71M27.20M62.07M182.63M
Stockholders Equity54.15M67.54M177.47M355.97M558.02M-65.25M
Cash Flow
Free Cash Flow-141.55M-170.63M-173.78M-221.69M-184.82M-14.57M
Operating Cash Flow-141.41M-170.49M-173.16M-219.99M-184.74M-14.57M
Investing Cash Flow-144.00K-140.00K280.68M-230.67M-50.71M0.00
Financing Cash Flow240.00K39.33M1.04M506.00K662.68M129.56M

Invivyd Technical Analysis

Technical Analysis Sentiment
Negative
Last Price0.74
Price Trends
50DMA
0.76
Negative
100DMA
0.83
Negative
200DMA
0.81
Negative
Market Momentum
MACD
-0.02
Positive
RSI
46.59
Neutral
STOCH
32.60
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IVVD, the sentiment is Negative. The current price of 0.74 is below the 20-day moving average (MA) of 0.79, below the 50-day MA of 0.76, and below the 200-day MA of 0.81, indicating a bearish trend. The MACD of -0.02 indicates Positive momentum. The RSI at 46.59 is Neutral, neither overbought nor oversold. The STOCH value of 32.60 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IVVD.

Invivyd Risk Analysis

Invivyd disclosed 92 risk factors in its most recent earnings report. Invivyd reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks

Invivyd Peers Comparison

Overall Rating
UnderperformOutperform
Sector (52)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
52
Neutral
$7.50B0.31-61.87%2.27%17.10%1.59%
48
Neutral
$58.32M-46.28%-33.00%54.91%
44
Neutral
$86.73M-122.69%20.91%
44
Neutral
$63.12M91.63%-55.47%24.92%
38
Underperform
$48.14M-130.16%65.54%
37
Underperform
$258.25M-141.69%-17.06%
35
Underperform
$101.70M-101.34%21.40%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
IVVD
Invivyd
0.74
-0.35
-32.11%
VTGN
VistaGen Therapeutics
2.00
-1.39
-41.00%
VTVT
vTv Therapeutics
15.07
-3.03
-16.74%
CLSD
Clearside Biomedical
0.81
-0.44
-35.20%
JSPR
Jasper Therapeutics
6.77
-14.35
-67.95%
INZY
Inozyme Pharma
4.00
-0.60
-13.04%

Invivyd Corporate Events

Private Placements and FinancingBusiness Operations and Strategy
Invivyd Secures $30 Million Loan from SVB
Positive
Apr 21, 2025

On April 18, 2025, Invivyd, Inc. entered into a $30 million loan agreement with Silicon Valley Bank, allowing for future capital drawdowns contingent on meeting specific conditions and milestones. This non-dilutive financing supports Invivyd’s strategic focus on enhancing per-share value and advancing its pipeline, including the monoclonal antibody candidate VYD2311, which is being developed for COVID-19 treatment and prevention.

Spark’s Take on IVVD Stock

According to Spark, TipRanks’ AI Analyst, IVVD is a Neutral.

Invivyd’s stock is under pressure due to significant financial difficulties, with ongoing losses and cash flow issues. The technical indicators suggest a bearish trend, and the valuation metrics highlight market concerns about future profitability. However, the appointment of Ajay Royan to the board is a positive corporate development that could improve strategic outcomes. Overall, the stock scores low due to financial and technical weaknesses, partially offset by potential strategic improvements.

To see Spark’s full report on IVVD stock, click here.

Executive/Board ChangesBusiness Operations and Strategy
Invivyd Appoints Ajay Royan to Board of Directors
Positive
Mar 26, 2025

On March 22, 2025, Invivyd, Inc. appointed Ajay Royan, founder of Mithril Capital, to its Board of Directors, with his term expiring at the 2025 annual meeting of stockholders. Royan, a venture capitalist with a focus on healthcare, technology, and energy, will receive compensation consistent with other non-employee directors and was granted an option to acquire 100,000 shares of common stock. His appointment is expected to enhance Invivyd’s efforts to advance its monoclonal antibody technology platform, which aims to provide high-quality medicines for vulnerable populations affected by COVID-19 and other diseases.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Apr 22, 2025